This Week’s Life Science Headlines

        Litigation Regulatory Recalls
Continue reading...

This Week’s Life Science Headlines

        Litigation
Continue reading...

This Week’s Life Science Headlines

        Litigation
Continue reading...

This Week’s Life Science Headlines

        Litigation
Continue reading...

This Week’s Life Science Headlines

        Litigation
Continue reading...

This Week’s Life Science Headlines

        Litigation
Continue reading...

This Week’s Life Science Headlines

        Litigation
Continue reading...

United States Supreme Court to Determine Whether It Should Hear Lupron Labeling Suit

The United States Supreme Court has been asked to determine whether a drug manufacturer’s older labeling is admissible to establish its failure to warn consumers of a product’s dangerous side effects.  See the Petition for Writ of Certiorari here.   In Klein v. TAP Pharmaceutical, 518 Fed.Appx. 583 (9th Cir. May 14, 2013), the plaintiff alleged a drug manufactured and marketed by TAP Pharmaceuticals, in a joint venture with Abbott Laboratories, did not contain adequate warnings regarding the dangerous side effects associated with Lupron…
Continue reading...

First New York Court Rejects Controversial Drug Developer Liability Rule

In a controversial 2008 decision in Conte v. Wyeth, Inc., 168 Cal. App. 4th 89 (Cal. Ct. App. 2008), a California Court of Appeals held defendant drug developer, Wyeth, Inc., liable for inadequate warnings in connection with the plaintiff’s use of a competitor’s generic version of the gastrointestinal reflux drug Reglan. The court in Conte held “the common law duty to use due care owed by a name-brand prescription drug manufacturer when providing product warnings extends not only to consumers of its own product,…
Continue reading...